I. EDUCATION & CREDENTIALS:
06/1983-12/1990 University of Sevilla Graduated School, Sevilla, Spain
Ph.D.(Clinical Biochemistry)
08/1986-06/1988 University of Miami School of Medicine, Miami, Florida
M.P.H.(Epidemiology)
10/l975-09/l981 University of Sevilla School of Medicine, Sevilla, Spain
M.D.(Medicine)
II. POST DOCTORAL EDUCATION:
06/1993-06/1995 Department of Psychiatry,
University of Miami School of Medicine/Jackson Memorial Hospital,
Miami, Florida
(Alcoholism and Addiction Med.)
01/1991-12/1994 Department of Psychiatry, University of Miami,
School of Medicine Jackson, Memorial Hospital
(Psychiatry)
08/1986-08/1988 Department of Epidemiology and Public Health, Nutrition Division,
University of Miami School of Medicine
(Nutrition and Biochemistry)
08/1986-08/1988 Department of Epidemiology and Public Health, Nutrition Division,
University of Miami School of Medicine
(Epidemiology)
07/1985-07/1988 Department of Pharmacology,
University of Miami School of Medicine
(Pharmacology)
09/1983-06/1985 Department of Oncology, Centro Duques Infantado, Spanish Association
Against Cancer, Sevilla, Spain
University of Sevilla School of Medicine
(Medicine)
III. CERTIFICATION & LICENSURE:
1996 American Board of Forensic Examiners (BC)
1994 American Board of Psychiatry and Neurology (BE)
1992 State of Florida Board Medicine
1990 FLEX Certification
1990 ECFMG Certification
IV. TEACHING RESPONSABILITIES:
2003-2005 Associate Professor
Ross University Medical School
1989-1993 Instructor, Public Health Nutrition
University of Miami School of Medicine
1989-1993 Instructor, Geriatric Education
University of Miami School of Medicine
1987-1989 Lecture in Basic Nutrition
Trinity Senior High School Level
1987-1989 Lecture in Nutrition
Florida International University
1987-1989 Lecture in Nutrition
Metro-Dade Police Department
1986-1988 Regular Scheduled Seminar Department of Pharmacology,
University of Miami School of Medicine
V. HONORS AND AWARDS:
1996 Elected Member Fellow of the American Board of Forensic Examiners
1993 Grantsmanship Training Workshop for New Investigator Award, NIAAA
1993 National Institute of Alcohol Abuse and Alcoholism (NIAAA) Investigator Award
1992 Post-doctoral work in Medicine and Surgery, completed with honors
1992 Elected Member American Society Clinical Nutrition
1991 Elected Fellow of the American College of Clinical Pharmacology
1990 Founding Fellow of the Southern Association for Geriatric Medicine
1990 Elected Member Southern Medical Association
1989 Elected Member Society Latin American Clinical Nutrition
1988 American Heart Association, Florida Affiliate Clinician Scientist Award
1988 American Heart Association, Florida Affiliate, Clinician Scientist Award
1988 Research Fellow in Clinical Nutrition
1988 Editorial Board of Archives of AIDS Research
1987 N.I.H.Post-doctoral Fellowship
1987 Citizen Ambassador, Division of International Ambassador Program
VI. PROFESSIONAL EXPERIENCE:
02/2012-Present Premier Clinical Research Institute
3100 NW 72nd Avenue, Suite 125, Miami, Florida 33122
Principal Investigator/Sub Investigator
Responsible for protecting the rights, safety and welfare of study participants.
Responsible for ensuring that the clinical trials are conducted according to the
investigational plan and all applicable regulations and laws.
Provide medical and scientific feasibility of all new sponsor inquiries.
Review and evaluate protocols and provide clinical and scientific support.
Liaise with sponsor regarding study design and site capabilities.
Interact with regulatory bodies as relevant to clinical operations.
Attend study initiation meetings. Be available for Sponsor visits.
Perform study physical examinations, review lab data, ECGs and other
Medical procedures. Review and sign CRFs/eCRFs at the conclusion of the Study.
1995-Present Private Practice, Miami, Florida
2011-2012 Doral Research Center, Miami, Florida
Principal Investigator
2008-2009 University of Miami Hospital, Miami, Florida
Medical Director
2003-2007 Cedars Medical Center, Miami, Florida
Medical Director
1999-2001 Windmoor Hospital, Miami, Florida
Medical Director
1995-1996 University of Miami School of Medicine, Miami, Florida
Attending Physician
1991-1995 Department of Epidemiology and Public Health, Miami, Florida
1993-1995 University of Miami School of Medicine, Miami, Florida
Research Fellow
1991-1994 Jackson Memorial Hospital, University of Miami School of Medicine,
Miami, Florida
Resident in Psychiatry
1991-1994 NIH/Fogarty International Graduate
Resident in Psychiatry
1989-1992 Ass. Dir.for Educ. & Training
Miami, Florida
1989-1991 University of Miami School of Medicine
Miami, Florida
Dir. Nutrition Division
1989-1991 University of Miami School of Medicine, Miami, Florida
Asst. Professor
1987-1988 University of Miami School of Medicine, Miami, Florida
Staff Physician
1985-1987 Clinical Pharmacology Associates, Miami, Florida
Research Associate
1984-1985 Clinical Pharmacology Associates, Miami, Florida
Clinical Research Coordinator
1982-1984 Department of Oncology Regional Center “Duques del lnfantado”, Spanish
Association against Cancer, Sevilla, Spain
4Staff Physician
1983-1984 National Institute of Health, Sevilla, Spain
Staff Physician
1982-1982 National Institute of Health, Madrid, Spain
Staff Physician
1981-1982 “Gomez Ulla” Medical Center, Madrid, Spain
Staff Physician
VII. CLINICAL RESEARCH EXPERIENCE:
Alzheimer’s disease
2018-Present Principal Investigator
A Multi-Center, Double-Blind, Parallel-Group, Randomized Controlled Study to Investigate
Efficacy and Safety of Orally Administered “Study Drug” during a 12-week Treatment Period
Compared to Placebo in Patients with Cognitive Impairment due to Alzheimer’s Disease.
2017-Present Principal Investigator
Open Label Extension Study for Continued Safety and Efficacy Evaluation of in “Study Drug”
Patients with Mild Alzheimer’s Disease.
2017-Present Principal Investigator
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy
and Safety of “Study Drug” in Subjects with Early Alzheimer’s Disease.
2016-Present Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the
Efficacy and Safety of “Study Drug” in the Treatment of Agitation in Patients with Dementia.
2016-Present Principal Investigator
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of “Study Drug” for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type.
2016-Present Principal Investigator
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Efficacy, Safety, and Tolerability of “Study Drug” for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type.
2015-2017 Principal Investigator
A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 mg and 100 mg of “Study Drug” in Subjects with Moderate Alzheimer’s.
2015-Present Principal Investigator
Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate
the Efficacy and Safety of “Study Drug” in Patients with Mild Alzheimer’s Disease Receiving
Acetylcholinesterase Inhibitors and/or Memantine.
2015-2017 Principal Investigator
Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study of “Study Drug” in
Patients with Mild-Moderate Alzheimer’s Disease Treated with an Acetylcholinesterase
Inhibitor; Study 3.
2015-2015 Principal Investigator
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of “Study Drug” or Placebo in Subjects With Mild to Moderate Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
2014-2017 Principal Investigator
A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer’s Type who were Previously Treated with “Study Drug” or Placebo in a Phase 3, Double-blind Trial
2014-2015 Sub- Investigator
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2
Doses of “Study Drug” or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease
Currently or Previously Receiving an Acetylcholinesterase Inhibitor.
2014-Present Principal Investigator
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of “Study Drug” in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type.
2014-2014 Principal Investigator
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the
Efficacy, Safety and Tolerability of “Study Drug” for the Treatment of Symptoms of Agitation in Patients With Alzheimer’s Disease.
2013-2014 Sub-Investigator
A Multicenter Prospective Observational Study to Assess Resource Utilization and Health-
related Quality of Life in Patients with Alzheimer’s Disease Receiving “Study Drug” – Strength Study.
2013-2014 Sub-Investigator
A Multicenter Prospective Observational Study to Assess Resource Utilization and Health-
Related Quality of Life in Patients with Alzheimer’s Disease of “Study Drug” – Strength Study.
2011- 2013 Principal Investigator
An Evaluation of the Safety and Efficacy of Memantine in agitated Patients With Moderate to Severe Alzheimer’s Disease.
2010-2011 Sub-Investigator
Efficacy and Safety of “Study Drug” Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer’s Disease.
2008-2010 Sub-Investigator
Study of “Study Drug” in the Treatment of Patients With Psychosis Associated With dementia of the Alzheimer’s type.
Bipolar Disorder
2017-Present Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the
Efficacy and Safety of “Study Drug” in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression).
2017-Present Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the
Efficacy and Safety of “Study Drug” Monotherapy in the Treatment of Patients with Major
Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression).
2013-2013 Principal Investigator
Open-label Study to Evaluate the Effectiveness of “Study Drug” Formulation of Aripiprazole as Maintenance Treatment in Patients with Bipolar I Disorder.
2008-2008 Sub-Investigator
Single center, open prospective study to evaluate the effectiveness of “Study Drug” monotherapy in the maintenance treatment of adolescent patients with bipolar spectrum disorder (bipolar I and bipolar II disorders, cyclothymia,and bipolar disorder not otherwise specified.
2003-2005 Principal Investigator
Double-Blinded Randomized Endpoint Classification Safety/Efficacy Study of the effectiveness and Safety of “Study Drug” in the Treatment of Mania/Bipolar Disorder.
2003-2004 Principal Investigator
Double-Blind Randomized Placebo-Controlled Trial of “Study Drug” in Treatment of Resistant
Bipolar Depression.
Major Depression Disorder
2011-2012 Principal Investigator
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of “Study Drug” as Adjunctive Therapy in Adults With Major Depressive Disorder.
2010-2012 Principal Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with “Study Drug” in Patients With Major Depressive Disorder.
2010-2010 Sub-Investigator
To determine effect sizes on scales measuring depressive symptoms, physical symptoms, psychosocial function and quality of life, and to evaluate safety in the population of patients
with epilepsy.
2007-2008 Sub-Investigator
To determine the safety and efficacy of “Study Drug” Monotherapy in the treatment of major
depressive disorder with psychotic features.
Traumatic Brain Injury
2017-Present Principal Investigator
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Efficacy, Safety, and Tolerability of “Study Drug” for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients with Traumatic Brain Injury (TBI).
Schizophrenia
2018-Present Principal Investigator
A Phase II Randomized, Double-Blinded, Placebo-Controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of “Study Drug” Once Daily over 12 week Treatment Period in Patients with Schizophrenia.
2017-Present Principal Investigator
A Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic
Bioequivalence Study Comparing Palaperidone Palmitate Extended-release “Study Drug” with Invega Sustenna (US Product Reference) in Subjects with Schizophrenia or Schizoaffective Disorder.
2017-Present Principal Investigator
Interventional ,Open-Label, Flexible Dose, Long Term Safety Study of “Study Drug” in Adult
Patients with Schizophrenia.
2016-Present Principal Investigator
An Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of “Study Drug”in
Patients with Schizophrenia.
2016-Present Principal Investigator
Interventional, randomised, Double-Blind, Active-Controlled, Fixed-Dose Study of “Study Drug” in Patients with Treatment-Resistant Schizophrenia.
2015-2017 Principal Investigator
A Phase 2, Efficacy, Safety, and Tolerability Study of “Study Drug” in Schizophrenia with
Alcohol Use Disorder Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride.
2015-2016 Principal Investigator
An Open-Label, Long-Term Safety and Tolerability Study of “Study Drug”in the Treatment of Subjects with Schizophrenia.
2014-2015 Principal Investigator
A 26-Week Extension Study of “Study Drug” as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
2014-2016 Principal Investigator
Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety “Study Drug” Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents.
2013-2014 Principal Investigator
Randomized, double blind, placebo controlled, parallel 26 week phase III study of 2 doses of an “Study Drug” or placebo as an adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on chronic stable atypical antipsychotic therapy.
2012- 2013 Principal Investigator
An open-label, multi-center, pilot, multiple-dose, bioavailability study to determine the pharmacokinetics of “Study Drug” injection 117 mg/0.75 ml in subjects with schizophrenia.
2011-2012 Sub-Investigator
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With
Oral Antipsychotics for 6 Months.
2008-2009 Sub-Investigator
Evaluation of “Study Drug” cognitive effects in a pilot placebo controlled trial in patients with
Schizophrenia.
2004-2005 Sub-Investigator
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM “Study Drug”.
Tardive Dyskinesia
2015-2016 Principal Investigator
A Phase 3, Open-Label, Safety and Tolerability Study of “Study Drug” NBI-98854 for the Treatment of Tardive Dyskinesia.
2014-2015 Sub-Investigator
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered “Study Drug” in Subjects with Drug-Induced Tardive Dyskinesia
2013-2014 Principal Investigator
A randomized endpoint classification: pharmaco-dynamics study to assess the risk of experiencing Tardive Dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients
2008-2010 Sub-Investigator
Evaluation of efficacy and tolerability of switching to Ziprasidone from other antipsychotic medications in the population of patients with Tardive Dyskinesia
2005-2005 Principal Investigator
Double-Blinded Randomized Endpoint Classification Safety/Efficacy Study of the effectiveness and Safety of “Study Drug” in the Treatment of Tardive Dyskinesia.
Diabetes
2010-2012 Sub-Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial
to Evaluate the Safety and Efficacy of “Study Drug” in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI)
or Angiotensin Receptor Blocker (ARB).
VIII. HONORS AND AWARDS:
1996 Elected Member Fellow of the American Board of Forensic Examiners
1993 Grantsmanship Training Workshop for New Investigator Award, NIAAA
1993 National Institute of Alcohol Abuse and Alcoholism (NIAAA) Investigator Award
1992 Post-doctoral work in Medicine and Surgery, completed with honors
1992 Elected Member American Society Clinical Nutrition
1991 Elected Fellow of the American College of Clinical Pharmacology
1990 Founding Fellow of the Southern Association for Geriatric Medicine
1990 Elected Member Southern Medical Association
1987 N.I.H. Post-doctoral Fellowship
1989 Elected Member Society Latin American Clinical Nutrition
1988 American Heart Association, Florida Affiliate Clinician Scientist Award
1988 American Heart Association, Florida Affiliate, Clinician Scientist Award
1988 Research Fellow in Clinical Nutrition
1988 Editorial Board of Archives of AIDS Research
1987 Citizen Ambassador, Division of International Ambassador Program
IX. BOOKS AND BOOK CHAPTERS:
1995 Baum MK, Shor-Posner G, Mantero-Atienza, E., Beach H..S. “Nutrition Immune Function and HIV Infection,” In WHO Psychoneuroimmunology and HIV-I Disease.
Eds. Schneiderman N, Szapocznik J, Antoni M, ‘Eisdorfcr C, Fletcher, MA, Goodkin K., and Maj M. Plenum,In Press.
1995 Baum MK, Shor-Posner G, Mantero-Atienza, E., Beach R.S. “TheAcquired Immunodeficiency Syndrome; Nutritional Aspects of Neuropsychological Function and Disease Progression,” 1n Stress, Coping and AIDS. Eds. Schneiderman N, McCabe P, Field T, and Eisdorfcr C. Lawrence Erlbaum Assoc., Inc.; Hillsdale, N.J. In Press.
1992 Baum MK, Shor-Posner G, Bonvehi P, Cassetti J, Lu Y, Mantero-Atienza, E., Beach RS, Sauberlich HE. Influence of HIV infection on vitamin status and requirements. New York Academy of Science,”Beyond Deficiency: New Views on the Function and Health Effects of Vitamins”, Eds. Sauberlich, H.E., Machlin, L.J., 669:165-174.
1992 Beach, R.S.,Cabrejos,C.,Shor-Posner,G.,Mantero-Atienza, E., Baum, M.K.”Nutritional Aspects of Early HIV Infection”, In: Nutrition and Immunity, Eds.R.K. Chandra,241-253.
1990 Mantero-Atienza, E., Maitland T, Beach RS, Fordyce-Baum MK. “Nutritional Implications of Parkinson’s Disease” Monograph of National Parkinson’s Foundation.
1989 Millon C, Mantero-Atienza, E., Szapoeznik J. “Psychological Junctures in HIV infection” IN AIDS: An Environmental and System Approach, P.Y. Stein, ed., Swets and Zeitlinger.
X. PLUBLISH ABSTRACTS:
1993 Singer C, Mantero-Atienza, E., Weiner WJ. Tandem gait in Parkinson’s
disease. Proceedings American Neurological Association.
1993 Shor-Posner G,Miguez-Burbano MJ, Mantero-Atienza, E., Fletcher MA,
Baum MK. Elevated IgE in relationship to plasma vitamin E levels in early
HIV-1 disease.IX International Conference on AIDS, Berlin, Germany.
1992 Baum MK, Shor-Posner G, Cassetti I., Bonvehi P, Lu Y, Beach RS, Mantero-
Atienza, E., Influence of HIV-1 Infection on vitamin status and requirements.
Proceedings of the New York Academy of Science.
1992 Peck M, Cabrejos C, Basit A, Chang J, Mantero-Atienza, E., Beach R, Lu Y, Shot-
Posner G, Baum MK. Desaturations and elongation of linoleic acid is impaired
in early HIV-l infection. Proceedings 3rd International Congress on Essential
Fatty Acids, Australia.
1992 Mantero-Atienza, E., Tndaeochea F, Cabrejos C, Sotomayor MC, Fletcher MA,
Sauberlich HE, Shor-Posner G, Baum MK. Selenium deficiency associated with
HIV-1 infection in children. VIII International Conference on AIDS,
Amsterdam, Netherlands,Vol. 3, PuB, 7336.
1992 Baum MK, Shor-Posner G, Cassetti Ll, Lu Y, Mantero-Atienza, E., Beach
RS, Sauberlich HE. Interim dietary recommendations to maintain adequate
blood nutrient levels in early HIV-1 infection. VII International Conference
on AIDS, Amsterdam, Netherlands, Vol. 3, Po8,3675.
1992 Shor-Posner G, Blaney N, Feaster D, Mantero-Atienza, E., Beach RS, Sauberlich
H, Goodkin K, Eisdorfer C, Baurn MK. Anxiety and depression in early
HIV-1 infection and its association with vitamin B6 status. VIII International
Conference on AIDS, Amsterdam, Netherland, Vol. 2, PoB, 3711.
1992 Singer C, Mantero-Atienza, E., Weiner WJ. A novel rating scale for
evaluation of tandem gait, study of interrater reliability and comparison of
normal subjects with parkinsonian and essential tremor patients. 2nd
International Congress of Movement Disorders, Vol. 7, Supple 1, P292.
1992 Shor-Posner G, Morgan R, Wilkie F, Beach RS, Mantero-Atienza, E., Baum MK.
Plasma cobalamin levels arc associated with information processing speed
in a longitudinal study of HIV-1 disease. Society for Neuroscience, Vol. I, 144.13.
1991 Mantero-Atienza, E., Sotomayor MC, Shor-Posner G, Fletcher MA, Beach R
Basit A, Cabrejos C, Baum MK. Selenium status and immune function in
early HIV-1infection. VII International Conference on AIDS, Florence, Italy, Vol. I,
#M.C.3126, 329.
1991 Baum MK, Beach RS, Mantero-Atienza, E., Fletcher M, Rosner D, Eisdorfer C,
Shor-Posncr G. Predictors of change in immune function: longitudinal analysis
of nutritional status in early HIV-1 infection. VII International Conference on
AIDS, Florence,Italy, Vol. 1, #M.C.3127, 329.
1991 Beach RS, Cabrejos C, Mantero-Atienza, E., Basit A, Chang J, Fletcher M, Baum
MK. Effect of zinc normalization on immunological function in early HIV-1
infection.VII International Conference on AIDS, Florence, Italy,Vol.1, #M.C.3 J 28,330.
1991 Shor-Posner G, Mantero-Atienza, E., Beach R, Javier JJ, Basit A, Cabrejos C,
Sauberlich HE, Feaster D,Baum MK. Zidovudine-associated alterations in
Nutrient status: impact upon immune function. VII International Conference on
AIDS, Florence, Italy, Vo12, #W.B.2098, 206.
1991 Indacochea FJ., Zambrano JC, Mantero-Atienza, E., Scott GB. Selenium deficiency
in HIV -infected children. Proceedings American Pediatric Society Meeting.
1991 Mavunda K, Javier JJ, Mantero-Atienza, E., Shor-Posner G, MeKey RM.
Trace elements in patients with cysticfibrosis (CF). Proceedings American
Pediatric Society Meeting. 1991.
1991 Mantero-Atienza, E., Mavunda K, Shor-Posner G, Javier n, Baum MK.
Inadequate fat soluble vitamin supplementation in cystic fibrosis (CF’).
Proceedings American “Pediatric Society JAIDS,4: 1122-3,
1991 Cabrejos C, Shor-Posner G, Mantero-Atienza, E., Beach R, Basit A, Chang J,
Baum MK. Altered levels of fatty acids affect immune function in early
HIV-I infection. Proceedings American Association of Pharmaceutical
Scientists.
1991 Basit Abdul, Mantero-Atienza, E., Beach RS, Cabrejos C, Chang J, Shor-Posner
G, Ballin MK. Lipid Status in Early HIV-1 Infection. Proceedings
American Association of Pharmaceutical Scientists.
1991 Wilkie F, Shor-Posner G, Mantero-Atienza, E., Beach RS, Ayala M, Morgan R,
Eisdorfer C, Baum MK. Association of vitamin B6 status and reaction time
in early HIV-1 infection. International conference on Neuroscience of HIV
Infection, Padova, Italy.
1991 Chang.T, Shor-Posner G, Cabrejos C, Baurn MK, Mantero-Atienza, E.,
Alterations in Body Composition in HIV-1 Infection. 74th Annual Meeting.
Proceedings of the American Dietetic Association, Inpress.
1991 Shor-Posner G, Ramsay RE, Morgan R, Slater J, Beach R, Mantero-Atienza, E.,
Baum MK. Association of Electrophysiologic Brain Function and
Nutritional Status In Human Immunodeficiency Virus (HIV-l) Infection.
21st Ann Mtng. Society for Neurosciences, Vol 1, #13.12,22
1991 Singer C, Mantero-Atienza, E., Weiner W. Tandem Gait in Middle Aged and
Elderly Subjects: A Nonnative Study. Proceedings 1992 AAN Scientific
Program.
1990 Shor-Posner G, Javier JJ, Beach RS, Mantero-Atienza, E., Baum MK. Altered
patterns of nutrient intake in HIV-1 + subjects with pyridoxine (Vitamin B6)
deficiency. Neuroscience Abstract, 16:614.
1990 Javier JJ, Shor-Posner G, Cabrejos C, Mantero-Atienza, E., Baum MK.
Effects of Zidovudine (AZT) on trace element levels in HIV infections. J Clinical
Pharmacology 1990; 30(9):840 #38.
1990 Javier 11, Chang J, Cabrejos C, Mantero-Atienza, E., Behavioral changes and
knowledge of HIV infected patients regarding diet, nutrition, and HIV infection.
American Dietetic Association 73rd Annual Meeting, Denver, Colorado, #/\-70.
1990 Mantero-Atienza, E., Baum MK, Beach RS, Javier JJ, Morgan R, Eisdorfer C.
Vitamin B6 and immune function in HIV infection. VI International Conference
on AIDS. San Francisco. Vol. 2, #3123.
1990 Baum MK, Beach RS, Morgan R, Mantero-Atienza, E., Wilke F, Eisdorfer C.
Vitamin BI2 and cognitive function in HIV infection. VI International
Conference on AIDS, San Francisco. Vol. 2, #F.B. 32.
1990 Beach RS, Baum MK, Shultz J, Mantero-Atienza, E., Prineas RJ, Thiebaud-
Alvarenga M, Alvarenga JC, Gutierrez R, Tercero D, Zelaya E. Patterns of
HIV Infection in Central America. VI Intemational Conference on AIDS, San
Francisco.Vol. 2, #F.C. 590.
1990 Baum MK, Beach RS, Morgan R, Mantero-Atienza, E., Wilke F, Eisdorfer C.
Vitamin BI2 and cognitive [unction in HIV infection. PSY-9. Neurological
and Neuropsychological Complications of HIV infection. Monterey, California.
1989 Mantero-Atienza, E.,Van Riel F, Beach RS, Fordyce-Baum MK. Dietary
Modification in HIV Seropositive Patients After Diagnosis. 2nd International
Awareness Conference on AIDS, Arch of AIDS Res Vol. 3; 224.
1988 Mantero-Atienza, E., K Millon C, Beach RS. Psychosocial cofactors affecting
HIV progression. First International Conference on theGlobal Impact of AIDS,
London, England.
1988 Beach RS, Mantero-Atienza, E., Fordyce-Baum MK. Dietary supplementation
in HIV infection. Federation Proceedings The FASEB Journal, Vol. 2,No.5:#6618.
1988 Fordyee-Baum MK, Beach RS, Mantero-Atienza, E., Retinol-Binding protein
in early HIV infection. Federation Proceedings The FASEB Journal, VoI2.
1988 Mantero-Atienza, E., Fordyce-Baum MK, Beach RS. Elevated folate levels and
immune function in early HTV infection. Federation Proceedings. The FASEB
Journal, Vol. 2,No.6:#7742.
1988 Crass R, Mantero-Atienza, E., Beach RS, Fordyce-Baum MK. Weight loss
and serum lipid modification by expanded wheat product. Federation
Proceedings The FASEB Journal, Vol. 4,No .4:#1941.
1988 Beach RS, Mantero-Atienza, E., Millon C. Psychosocial cofactors affecting
HIV Progression. Proceedings First Pan American Conference on AIDS,
Guadalajara, Mexico.20: MS•’l.
1988 Beach RS, Mantero-Atienza, E., Crass R, Fletcher MA, Morgan R, Eisdorfer C,
Fordyce-Baum MK. Trace Elements during early HTV infection. Proceedings
First Pan American Conference on AIDS, Guadalajara, Mexico. 24:P-8.
1988 Beach RS, Mantero-Atienza, E., Crass R, Fletcher MA, Morgan R, Eisdorfer C,
Fordyce-Baum MK. Retinol-Binding protein in early HIV infection. Proceedings
First Pan American Conference on AIDS, Guadalajara, Mexico. 25:P-9, 1988.
1988 Beach RS, Mantero-Atienza, E.,Crass R, Fletcher MA, Morgan R, Eisdorfer C,
Fordyce-Baum MK. Elevated folate levels and immune function in early HIV
infection. Proceedings First Pan American Conference on AIDS, Guadalajara,
Mexico. 20:P-1 0.
1988 Mantero-Atienza, E., Beach RS, Crass R, Fletcher MA, Morgan R, Fordyce-
Baum MK. Retinol binding protein levels immune function: in HIV-1
infection. Proceedings Fourth International Conference on AIDS, Vol. 2, #2608,
1988 Beach RS, Mantero-Atienza, E., Crass R, Fletcher MA, Morgan R, Fordyce-
Baum MK.Vitamin B 12 levels and immune function in early HIV infection.
Proceedings Fourth International Conference on AIDS, Vol. 2, #2601.
1988 Fordyce-Baum MK, Mantero-Atienza, E., Crass R, Morgan R, Beach RS. Toxic
levels on dietary supplementation in early HTV infection. Proceedings Fourth
International Conference on AIDS,Vol. 2, #7523.
1988 Yañez-Polo I, Mantero-Atienza, E.,Educational cooperation between Puerto
Rico find Spain. Proceedings of the Ten years after Alma Ata: Health Progress,
Problems and Future Priorities. 1988. Annual International Health Conference,
Washington, DC. 1988.
1988 Mantero-Atienza, E., Beach RS, Fordyce-Baum MK. Water-soluble vitamin
levels in a geriatric population. J Clin. Pharmacol 28: Vol 28 #154.
1988 Beach RS, Fordyce-Baum MK, Mantero-Atienza, E., Cholesterol and triglyceride
levels in nursing home residents. J Clin Pharrnacol 28: VoI 28, # 153.
1988 Van Riel F, Mantero-Atienza, E., Salvato F, Beach RS, Fletcher MA, Klimas N,
Fordyce-Baum MK, Nutritional Status of Chronic Fatigue Syndrome
(CFS)/Epstein-Barr Virus(EBV) patient. J. Exp. Clin.Cancer Res., 7,3,:88-
Supplement.
1987 Mantero-Atienza, E., & Pressman BC. Comparison of the effects of two dietary
omega-S lipids, linseed (18:3) and MaxEPA (20:5, 22:6) oils on blood lipids
and blood pressure. Federation Proceedings 46:4, 1170,
1987 Fordyce-Baum MK, Mantero-Atienza, E., and Christakis G. Nutritional status of
elderly in a nursing home. Federation Proceedings 46:3, 900,1987.
1987 Eisdorfcr C, Szapocznik J, Scott G, Klimas N, Fordyce-Baum MK, Mantero-
Atienza,E., et al.The Biopsychosocial Research Center on AIDS: A
Multidisciplinary approach to the investigation of the AIDS disease, III
International Conference on Acquired Immunodeficiency Syndrome (AIDS),
Washington, DC, USA.
1987 Mantero-Atienza, E., Eisdorfer C, Christakis G, Crass Rand & Fordyce-Baum
MK. Nutritional status and the development of AIDS in lymphadenopathy
patients. HI International Conference of Acquired Immunodeficiency Syndrome
(AIDS), Washington, DC, USA.
1987 Mantero-Atienza, E., Christakis G, Fordyce-Baum MK. The effect of a Pectin
containing food supplement on serum lipids and lipoproteins in healthy
normolipidemic males. Proceedings of Southeastern Pharmacology Society,
University, Mississippi.
1987 Langer L, Mantero-Atienza, E., Crass R, Duncan R, Fordyce-Baurn MK. Effect of
Weight reduction by low-caloric diet on blood lipids in norrnolipidemic. females
Proceedings of Southeastern Pharmacology Society, University, Mississippi
1987 Mantero-Atienza, E., Pressman BC. Role of omega-3 Lipid Metabolism in
Brain Functioning During Aging, Florida Council on Aging. American Federation
on Aging Research. Ft. Lauderdale, Florida.
XI. OTHER TRAINING:
NIDA- Good Clinical Practice
XII. HOSPITAL PRIVILEGES
Mercy Hospital
Kendall Regional Medical Center
Southern Winds Hospital
XIII. PROFESSIONAL MEMBERSHIPS & FACILITY AFFILIATIONS:
AFFILIATIONS
02/17-Present Premier Clinical Research Institute Inc.
3100 NW 72nd Avenue Suite 125
Miami, FL 33122
Principal Investigator/Sub-Investigator
08/12-Present Residential Plaza
5617 NW 7th Street, Miami Florida 33126
08/12-Present Sevilla ALF, LLC
12199 SW 51st Street, Miami Florida 33175
08/12-Present Granada ALF, LLC
11935 SW 49th Street, Miami Florida 33175
08/12-Present Caring Hearts Assisted Living
8601 SW 36th Street, Miami Florida 33155
08/95-Present Armando Ropero-Cartier, M.D. P.A.
Family Doctor
08/95-Present University of Miami Hospital
Medical Doctor
08/95-Present Jackson Memorial Hospital
Medical Doctor